Biomarkers for predicting prognosis of kidney disease

2:

• The kit according to claim 1, wherein the binding molecule is an anti-cMet antibody.

3:

• The kit according to claim 1, wherein the renal disease is at least one selected from the group consisting of acute kidney injury, end-stage kidney disease (ESKD), systemic erythematous lupus, diabetic nephropathy (DN), IgA nephropathy (IgAN), HIV-relevant nephritis, non-diabetic chronic nephropathy, focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and xanthine oxidase deficiency disease.

4:

• The kit according to claim 1, further comprising a binding molecule specifically bound to creatinine.

5:

• A composition for diagnosing a renal disease or predicting prognosis of the renal disease from urine, comprising:
• a binding molecule specifically bound to cMet protein contained in the urine,
• wherein, when a level of the cMet protein is higher than a normal group, this condition is diagnosed as the renal disease or predicted to have poor prognosis of the renal disease by the composition.

6:

• A method for diagnosing a renal disease or predicting prognosis of the renal disease from urine, comprising:
• measuring a level of cMet protein contained in a urine sample obtained from an object,
• wherein, when the level of the cMet protein is higher than a normal group, this condition is diagnosed as the renal disease or predicted to have poor prognosis of the renal disease.

7:

• The method according to claim 6, wherein the measuring of the level of the cMet protein comprises using a binding molecule specifically bound to the cMet protein.

8:

• The method according to claim 6, wherein the binding molecule is an anti-cMet antibody.

9:

• The method according to claim 6, wherein the normal group is an object without any renal disease.

10:

• The method according to claim 6, wherein the renal disease is at least one selected from the group consisting of acute kidney injury, end-stage kidney disease (ESKD), systemic erythematous lupus, diabetic nephropathy (DN), IgA nephropathy (IgAN), HIV-relevant nephritis, non-diabetic chronic nephropathy, focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and xanthine oxidase deficiency disease.

11:

• The method according to claim 6, further comprising measuring a urine creatinine concentration, a total urinary protein concentration, or the urine creatinine concentration and the total urinary protein concentration.

14:

• The method according to claim 13, wherein the measuring of the level of the cMet protein comprises using a binding molecule specifically bound to cMet.

15:

• The method according to claim 14, wherein the binding molecule is an anti-cMet antibody.

16:

• The method according to claim 13, wherein the normal group is an object without any renal disease.

17:

• The method according to claim 13, wherein the renal disease is at least one selected from the group consisting of acute kidney injury, end-stage kidney disease (ESKD), systemic erythematous lupus, diabetic nephropathy (DN), IgA nephropathy (IgAN), HIV-relevant nephritis, non-diabetic chronic nephropathy, focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and xanthine oxidase deficiency disease.

18:

• The method according to claim 13, further comprising measuring a urine creatinine concentration, a total urinary protein concentration, or the urine creatinine concentration and the total urinary protein concentration.